Orforglipron

GLP-1 / metabolic (non-peptide) · By Preptide Pro editorial team · Last updated 2026-11-03

Orforglipron is a glp-1 / metabolic (non-peptide) peptide, and it has an FDA-approved product. An oral small-molecule GLP-1 receptor agonist, not a peptide. Studied in late-stage trials for obesity and type 2 diabetes, and openFDA lists an approved product (see the FDA section).

FDA-approved (see products)

Chemistry (PubChem)

PubChem CID	137319706
CAS number	2212020-52-3
Molecular formula	C48H48F2N10O5
Molecular weight	883 g/mol
Other names	Orforglipron, LY3502970, LY-3502970, RefChem:168463, GLP-1 receptor agonist 1, Foundayo, MFCD31807602, Orforglipron (USAN)

Is Orforglipron FDA-approved?

FDA application records from openFDA
Brand	Application	Status	Sponsor
FOUNDAYO	NDA220934	Prescription	ELI LILLY AND CO

How much research is there on Orforglipron?

PubMed lists 156 records for “orforglipron”, of which 20 are tagged as human clinical trials.

Most recent PubMed records
Recent study	Journal	Date
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.	Lancet	2026 Dec 20
Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m(2) and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial.	Obes Pillars	2026 Dec
Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension.	Am J Prev Cardiol	2026 Dec
In T2D inadequately controlled with metformin, orforglipron reduced HbA(1c) more than dapagliflozin at 40 wk.	Ann Intern Med	2026 Nov 3
Orforglipron alleviates aortic aneurysm and dissection via inhibiting WNT5A noncanonical signaling.	Biochem Pharmacol	2026 Nov

Sources

This is general research information, not medical advice. Check with a clinician before using any compound.